Agreement Supports Phase IIb and Future Phase III Trial Development, Addressing Critical Needs in Palliative Care Using Optimi's Natural Psilocybin Extract Vancouver, British Columbia--(Newsfile Corp. - December 17, 2024) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) (" Optimi " or the " Company "), a Canadian manufacturer of GMP-certified, naturally-derived psilocybin and MDMA, has entered into binding... Read More

Additional 700 Doses Ordered by Mind Medicine Australia as Demand Surges Vancouver, British Columbia--(Newsfile Corp. - October 23, 2024) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) (" Optimi " or the " Company "), a Health Canada-licensed manufacturer of psychedelic pharmaceuticals specializing in botanical psilocybin and MDMA, is proud to announce that the first group of patients with post-traumatic stress... Read More

Vancouver, British Columbia--(Newsfile Corp. - October 21, 2024) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) (" Optimi " or the " Company "), a GMP-compliant, Health Canada-licensed manufacturer of psychedelics specializing in botanical psilocybin and MDMA, today announced that Mr. William (Bill) Ciprick will be stepping down as Chief Executive Officer due to personal reasons. "During his three years of... Read More

Trial to study Major Depressive Disorder using Optimi's GMP natural psilocybin capsules in conjunction with therapy Vancouver, British Columbia--(Newsfile Corp. - August 28, 2024) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) (" Optimi " or the " Company "), a GMP-compliant, Health Canada-licensed manufacturer of psychedelics pharmaceuticals specializing in botanical psilocybin and MDMA, is pleased to announce... Read More

Vancouver, British Columbia--(Newsfile Corp. - August 16, 2024) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) (" Optimi " or the " Company "), a GMP-approved, Health Canada-licensed psychedelics pharmaceutical manufacturer specializing in botanical psilocybin and MDMA, is pleased to announce it has completed the inaugural export of it's GMP-validated MDMA capsules to Australia for the treatment of PTSD, along... Read More

VANCOUVER, British Columbia and NEW YORK, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi”), a GMP-approved, Health Canada licensed psychedelics pharmaceutical manufacturer specializing in botanical psilocybin and MDMA, and Psyence Biomedical Ltd. (NASDAQ: PBM) (“Psyence”), a developer of nature-derived psilocybin-based therapeutics, are pleased to announce that the... Read More

Vancouver, British Columbia--(Newsfile Corp. - August 7, 2024) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) (" Optimi " or the " Company "), a GMP-approved, Health Canada licensed psychedelics pharmaceutical manufacturer specializing in botanical psilocybin and MDMA, announces it intends to complete a non-brokered private placement of up to 16,666,666 units (each a " Unit ") at CAD$0.30 per Unit for gross... Read More

Observational studies to focus on patients with addiction and end-of-life distress pending formal approval and permitting from Thai health authorities Vancouver, British Columbia--(Newsfile Corp. - July 23, 2024) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) (" Optimi " or the " Company "), a GMP-approved, Health Canada licensed psychedelics pharmaceutical manufacturer specializing in botanical psilocybin and... Read More

Vancouver, British Columbia--(Newsfile Corp. - June 27, 2024) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) (" Optimi " or the " Company "), a Health Canada-approved, GMP-compliant pharmaceutical drug manufacturer specializing in the controlled substances MDMA and botanical psilocybin, is pleased to announce the... Read More

The Company will ship 160 doses of MDMA and psilocybin to Australian psychiatrists for the treatment of patients with PTSD and Treatment-Resistant Depression. Vancouver, British Columbia--(Newsfile Corp. - June 25, 2024) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ( "Optimi" or the "Company" ), a Health Canada-approved, GMP-compliant pharmaceutical drug manufacturer specializing in the controlled substances... Read More

Vancouver, British Columbia--(Newsfile Corp. - June 11, 2024) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) (" Optimi " or the " Company "), a leading Health Canada licensed GMP psychedelics pharmaceutical manufacturer, specializing in controlled substances such as botanical psilocybin and MDMA, is pleased to announce a series of milestones in its international psychedelic supply operations and corporate... Read More

VANCOUVER, BC , June 3, 2024 /CNW/ - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) ( "Optimi" or the "Company" ), a leading Health Canada-licensed psychedelics pharmaceutical manufacturer specializing in controlled substances such as botanical psilocybin and MDMA, is pleased to announce that it has been awarded a Drug Establishment Licence (DEL) from Health Canada for the manufacturing and sale of its MDMA and... Read More

VANCOUVER, BC , May 31, 2024 /CNW/ - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading Health Canada-licensed GMP psychedelics pharmaceutical manufacturer specializing in controlled substances such as botanical psilocybin and MDMA, is pleased to announce it has closed a third and final tranche of its non-brokered private placement (the " Offering "). The Offering consisted of units (each a " Unit ") at... Read More

VANCOUVER, British Columbia, May 29, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading Health Canada licensed GMP psychedelics pharmaceutical manufacturer, specializing in controlled substances such as psilocybin and MDMA, is pleased to announce that it has received an import permit from Mind Medicine Australia (MMA) to export its GMP MDMA and psilocybin capsules to supply approved... Read More

VANCOUVER, British Columbia, May 22, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading Health Canada licensed psychedelics pharmaceutical manufacturer, specializing in controlled substances such as botanical psilocybin and MDMA, has entered a Letter of Intent (LOI) with ATMA Journey Centers (ATMA). ATMA is a pioneering Canadian firm focused on advancing innovative solutions in... Read More

VANCOUVER, British Columbia, May 14, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading Health Canada-licensed GMP psychedelics pharmaceutical manufacturer specializing in controlled substances such as botanical psilocybin and MDMA, is pleased to announce it has received a Certificate of Analysis (COA) from independent third-party laboratory testing, confirming that Optimi’s... Read More

VANCOUVER, British Columbia, May 10, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“ Optimi ” or the “ Company ”), a leading Health Canada licensed GMP psychedelics pharmaceutical manufacturer, specializing in controlled substances such as botanical psilocybin and MDMA, announces that it intends to close the final tranche of its non-brokered private placement imminently (the “ Offering... Read More

VANCOUVER, British Columbia, May 09, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading Health Canada licensed GMP psychedelics pharmaceutical manufacturer, specializing in controlled substances such as botanical psilocybin and MDMA, is pleased to report a significant update to its collaboration with The Institute for Psychedelic Research at Tel Aviv University (IPR-TLV). Optimi has... Read More

VANCOUVER, British Columbia, April 23, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading Health Canada licensed psychedelics pharmaceutical manufacturer, is thrilled to announce an innovative research and development partnership with the Kwantlen Polytechnic University Applied Genomics Centre (KPU-AGC). The project, entitled, “Genetic Identification of Psilocybin Containing... Read More

VANCOUVER, British Columbia, April 15, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading Health Canada licensed psychedelics pharmaceutical manufacturer, specializing in controlled substances such as natural psilocybin and MDMA, has announced the completion of three batches of its MDMA Active Pharmaceutical Ingredient (API) manufactured from raw materials under the Company’s... Read More

VANCOUVER, British Columbia, April 09, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading Health Canada licensed psychedelics pharmaceutical manufacturer, specializing in controlled substances such as natural psilocybin and MDMA, is proud to announce the signing of an international natural psilocybin supply agreement with New Zealand-Based Mātai Medical Research Institute (Mātai),... Read More

VANCOUVER, British Columbia, April 02, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading Health Canada licensed psychedelics pharmaceutical manufacturer, specializing in controlled substances such as natural psilocybin and MDMA, is pleased to announce that three validation batches of its Natural Psilocybin Extract have undergone full release testing and have been issued the... Read More

VANCOUVER, British Columbia, March 28, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading Health Canada licensed psychedelics pharmaceutical manufacturer, specializing in controlled substances such as natural psilocybin and MDMA, proudly announces its role as a Presenting Sponsor at the highly anticipated 4th Annual Psychedelic Therapeutics and Drug Development Conference. The event... Read More

VANCOUVER, British Columbia, March 26, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading Health Canada licensed psychedelics pharmaceutical manufacturer, specializing in controlled substances such as natural psilocybin and MDMA, is thrilled to announce it has entered an international MDMA supply agreement with The Institute for Psychedelic Research at Tel Aviv University... Read More

VANCOUVER, British Columbia, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“ Optimi ” or the “ Company ”), a Health Canada licensed drug researcher and formulator specializing in controlled psychedelic substances such as natural psilocybin and MDMA, announces that on February 23, 2024 it closed the first tranche (“ First Tranche ”) of a non-brokered private placement (the “... Read More

VANCOUVER, British Columbia, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a Health Canada licensed drug researcher and formulator specializing in controlled psychedelic substances such as natural psilocybin and MDMA, extends its congratulations to Lykos Therapeutics (formerly MAPS Public Benefit Corporation) on the recent announcement of the U.S.... Read More

VANCOUVER, British Columbia, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“ Optimi ” or the “ Company ”), a Health Canada licensed drug researcher and formulator specializing in controlled psychedelic substances such as natural psilocybin and MDMA, announces it intends to complete a non-brokered private placement of up to 5,000,000 units (each a “ Unit ”) at CAD$0.30 per Unit... Read More

Highlights: Optimi Chief Science and Quality Assurance experts to provide in-depth access into the Company’s safety and quality standards. Optimi experts will address critical inquiries which still exist on the definition of validated GMP psilocybin, MDMA, and other psychedelic substances. Optimi is the only end-to-end, publicly listed psychedelics company currently offering its drug candidates at scale to address... Read More

VANCOUVER, British Columbia, Jan. 19, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a Health Canada licensed drug researcher and formulator specializing in controlled psychedelic substances such as natural psilocybin and MDMA, is pleased to announce it has been granted an amendment to its Health Canada Controlled Drugs and Substances Licence. Effectively... Read More

VANCOUVER, British Columbia, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi”), a Health Canada licensed drug researcher and formulator specializing in controlled psychedelic substances such as natural psilocybin and MDMA, proudly announces a significant milestone in the granting of its Precursor Licence for 3,4-Methylenedioxyphenyl-2-propanone (“MDP2P”), the precursor... Read More

VANCOUVER, British Columbia, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi”), a licensed Canadian drug researcher and formulator specializing in controlled psychedelic substances such as natural psilocybin and MDMA, today announced the signing of a supply agreement with... Read More

VANCOUVER, British Columbia, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading end-to-end drug researcher and formulator licensed by Health Canada, has reached a significant milestone in its mission. The company is proud to announce the successful harvest of eight new... Read More

VANCOUVER, British Columbia, Nov. 10, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) ("Optimi" or the "Company") is pleased to announce the successful resolution of a dispute that arose in connection with a termination notice related to a supply agreement ("the Supply Agreement") signed with a private entity on May 4, 2023. Optimi is pleased to confirm that the dispute has been amicably... Read More

VANCOUVER, British Columbia, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading Canadian psychedelics drug research and formulation company, is delighted to announce the appointment of Dr. Preston A. Chase as the Company’s Chief Science Officer (“CSO”). Dr. Chase is a distinguished Research & Development (“R&D”) chemist and seasoned business professional with an impressive... Read More

VANCOUVER, British Columbia, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“ Optimi Health ” or the “ Company ”), a Canadian drug research and formulation company licensed by Health Canada to manufacture psychedelic substances such as MDMA and high-quality, GMP-grade natural psilocybin, is pleased to announce it has entered into a non-dilutive Debt Financing Agreement (“ DFA ”)... Read More

VANCOUVER, British Columbia, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a Canadian psychedelics drug research and formulation company, is pleased to see the positive and encouraging outcomes from the MAPS Phase 3 MDMA-Assisted Therapy (MDMA-AT) Clinical Trial published today on Nature Medicine. The Company considers the results to be a substantial step forward in the... Read More

VANCOUVER, British Columbia, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a Canadian psychedelics drug research and formulation company, proudly announced today that Health Canada has approved an amendment to the Company’s Dealer's Licence. The amendment empowers Optimi to embark on the formal supply journey for Canada’s Special Access Program (SAP), operating within the... Read More

VANCOUVER, British Columbia, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“ Optimi Health ” or the “ Company ”), a Canadian drug research and formulation company licensed by Health Canada to manufacture psychedelic substances such as MDMA and high-quality, GMP-grade natural psilocybin, is pleased to announce it has entered into a non-dilutive Debt Financing Agreement (“ DFA ”)... Read More

VANCOUVER, British Columbia, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a Canadian drug research and formulation company licensed by Health Canada to manufacture psychedelic substances such as MDMA and high-quality, GMP-grade natural psilocybin, is pleased to announce the non-dilutive Debt Financing Agreement (“ DFA ”) and General Security Agreement (“ GSA ”) for proceeds of... Read More

VANCOUVER, British Columbia, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), an end-to-end drug researcher and formulator licensed by Health Canada to produce and supply, for clinical research purposes and in controlled patient markets, psychedelic substances such as 3,4-Methylenedioxymethamphetamine (“MDMA”), natural GMP-grade psilocybin, along with... Read More

VANCOUVER, British Columbia, July 27, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”) has received a termination notice and demand for payment pursuant to a definitive supply agreement (the “Supply Agreement”) with a private entity focused on developing mushroom-based therapeutics. For further details of the Supply Agreement, see the Company’s press release dated... Read More

VANCOUVER, British Columbia, June 15, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), an end-to-end drug researcher and formulator licensed by Health Canada to produce and supply, for clinical research purposes and in controlled patient markets, psychedelic substances such as GMP-grade 3,4-Methylenedioxymethamphetamine (“MDMA”) and natural psilocybin, along with... Read More

VANCOUVER, British Columbia, May 17, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), an end-to-end drug researcher and formulator licensed by Health Canada to produce and supply, for clinical research purposes and in controlled patient markets, psychedelic substances such as 3,4-Methylenedioxymethamphetamine (“MDMA”), GMP-grade psilocybin, along with natural... Read More

VANCOUVER, British Columbia, May 10, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp . ( CSE: OPTI ) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), an end-to-end drug researcher and formulator licensed by Health Canada to produce and supply, for clinical research purposes, psychedelic substances such as 3,4-Methylenedioxymethamphetamine (“MDMA”), natural GMP-grade psilocybin, along with natural health product... Read More

VANCOUVER, British Columbia, May 04, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“ Optimi ” or the “ Company ”), today announced that it has entered into a CAD$1.2 million definitive supply agreement with a private entity focused on developing mushroom-based therapeutic drugs through pre-clinical research and clinical trials. Under Canada’s Controlled Drugs and Substances regulations,... Read More

Highlights: Signed Purchase Orders with Mind Medicine Australia to ensure that patients with treatment resistant post-traumatic stress disorder (PTSD) have access to medical grade GMP MDMA (using Optimi Health’s MDMA formulation, OPTI-MHCL) and patients with treatment resistant depression have access to GMP encapsulated psilocybin as part of therapy through their authorized treating psychiatrists when rescheduling becomes... Read More

VANCOUVER, British Columbia, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), an end-to-end Canadian-based drug manufacturer and formulator licensed by Health Canada to produce and supply natural, GMP-grade psilocybin, synthetic psychedelic substances, and high-quality functional mushrooms, is pleased to announce the submission of its clinical trial... Read More

The Company is producing OPTI-MHCL in-house under its Health Canada issued Dealers Licence using Optimi’s scalable, proprietary production method. Optimi is also manufacturing MDMA under GMP-compliant protocols, making additional MDMA product available for clinical research, drug development, and therapist training initiatives. OPTI-MHCL drug candidates will intially be offered in 50mg, 80mg, and 125mg dosage formats and can... Read More

VANCOUVER, British Columbia, Jan. 17, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp . (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), an end-to-end Canadian-based drug manufacturer and formulator licensed by Health Canada to produce and supply natural, GMP grade psilocybin, synthetic psychedelic substances, most notably MDMA, and high-quality functional mushrooms, is pleased to announce the expansion of its... Read More

VANCOUVER, British Columbia, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp . (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), is pleased to announce that Mr. Bryan Safarik, Mr. Jacob Safarik, Mr. Jon Schintler, Mr. Dane Stevens, and Mr. JJ Wilson have been re-elected to the Board of Directors following the Company’s Annual General Meeting held January 9, 2023. The Company would like to thank... Read More

Highlights: $1.85 million in proceeds received through a strategic offering of units at $0.325 per unit with each unit comprised of one common share and one-half of one (1/2) Common Share purchase warrant exercisable at $0.50, for total potential proceeds of $3.27 million. Financing will fuel Optimi’s ongoing commercialization efforts, support new product development and provide necessary working capital to be strategic in... Read More

Highlights: The safe supply of psychedelic drug products manufactured at a GMP-level is critical in treating serious mental health issues. Minister of Mental Health and Addictions, the Honourable Carolyn Bennett, has publicly stated that safe drug supply is paramount to reducing overdose deaths. Optimi Health is the largest cultivator of natural EU-GMP psilocybin and MDMA in North America. Optimi Health is licensed by Health... Read More

Optimi Health Corp . (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a Canadian-based company licensed by Health Canada to produce and supply natural, EU-GMP grade psilocybin and other psychedelic substances, most notably MDMA, is pleased to announce that in conjunction with ATMA Journey Centers (“ATMA”), the companies have confirmed their intent to proceed with a Phase I clinical trial application (CTA)... Read More

Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), is pleased to announce that it has completed what it believes to be the largest legal natural psilocybin harvest in Canadian history. The Company is licensed by Health Canada to produce and supply natural, EU-GMP grade psilocybin and other psychedelic substances, most notably MDMA, as well as functional mushrooms that focus on the health... Read More

Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a Canadian-based company licensed by Health Canada to produce natural, scalable, and accessible psychedelic and functional mushroom products for transformational human experiences, is pleased to announce that it has entered into an agreement... Read More

Company set to introduce psychedelic product catalogue showcasing in-house EU-GMP manufacturing expertise Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a Canadian-based company licensed by Health Canada to produce and supply natural, EU-GMP grade psilocybin and synthetic psychedelic substances, as well as functional mushrooms that focus on the health and wellness markets, is pleased... Read More

Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a Canadian-based company licensed by Health Canada to produce natural, scalable, and accessible psychedelic and functional mushrooms for transformational human experiences, is pleased to announce that it has entered into its first... Read More

Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a Canadian-based company licensed by Health Canada to produce natural, scalable, and accessible psychedelic and functional mushrooms for transformational human experiences, is pleased to announce that it has finalized three new Canadian... Read More

Optimi Health Corp . (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a Canadian-based company licensed by Health Canada to produce natural, scalable, and accessible psychedelic and functional mushrooms for transformational human experiences, has received permission from Health Canada to manufacture and... Read More

Blue Serenity brings science and compassion together, will cement Thomas Hartle’s legacy as a Canadian psychedelic icon Optimi and Hartle to host press conference today at 1:00 PM EST Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a Canadian-based company licensed by Health Canada to... Read More

Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a homegrown, Canadian company licensed by Health Canada to produce natural, scalable, and accessible psychedelic and functional mushrooms, as well as synthetic formulations for transformational human experiences, is pleased to announce that... Read More

Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a homegrown, Canadian company cultivating and synthesizing high quality psychedelics and natural functional and psilocybin mushroom strains for transformational human experiences, is pleased to announce that it has finalized a supply agreement with Bloom Psychedelic Therapy And Research Centre (“Bloom”), a Calgary-based provider of mental... Read More

Optimi Health Corp . (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a homegrown, Canadian company producing natural, scalable, and accessible psychedelic and functional mushrooms, as well as synthetic formulations for transformational human experiences, is pleased to announce that it has entered into a supply agreement with SABI Mind, a Calgary-based clinic group providing psychedelic-assisted therapies.... Read More

Optimi Health Corp . (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a homegrown, Canadian company producing natural, scalable, and accessible mushroom formulations for transformational human experiences, has submitted a request with Health Canada for an amendment to its Controlled Substances Dealer’s Licence. The amendment would enable the Company to synthesize, process and distribute pharmaceutical grade... Read More

Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a homegrown, Canadian company producing natural, scalable, and accessible mushroom formulations for transformational human experiences, is pleased to announce that it has entered into an exploratory supply agreement with ATMA Journey Centers (“ATMA”), a privately held facilitator of psilocybin-assisted therapy and practitioner training... Read More

Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a homegrown, Canadian company producing natural, scalable, and accessible mushroom formulations for transformational human experiences, is pleased to announce that it has entered into a supply agreement with Filament Health (“Filament”) (OTCQB:FLHLF) (NEO:FH) (FSE:7QS), a clinical-stage natural psychedelic drug development company. Optimi... Read More

Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a homegrown, Canadian company producing natural, scalable, and accessible mushroom formulations for transformational human experiences, is pleased to announce that it has entered into a supply agreement with Halucenex Life Sciences Inc.... Read More

Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a homegrown, Canadian company producing natural, scalable, and accessible mushroom formulations for transformational human experiences, is pleased to announce an historical milestone in the Company’s road to commercialization with the successful completion of its first batch of psilocybin cubensis and functional mushrooms. With the vast... Read More

Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a homegrown, Canadian company producing natural, scalable, and accessible mushroom formulations for transformational human experiences, is pleased to announce that Crispin Blunt, Member for Reigate for the Conservative Party of the United Kingdom, will be appearing as a keynote speaker at the Grand Opening of the Company’s 20,000 square... Read More

Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a homegrown, Canadian company producing natural, scalable, and accessible mushroom formulations for transformational human experiences, is pleased to announce that it has completed the acquisition of a diverse catalog of psilocybin and... Read More

Optimi Health Corp . (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), is pleased to announce that it has completed a planned expansion of the on-site analytical laboratory at its Princeton, British Columbia facility. The on-site lab is purpose built inside one of Optimi’s EU-GMP capable 10,000 square foot, state-of-the-art indoor growing facilities dedicated to the cultivation of safe, high-quality... Read More

Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”) CEO, Bill Ciprick, issued a statement today in response to Health Canada’s May 6 Notice to Stakeholders “regarding the proposed use of psilocybin mushrooms in clinical trials, or as a drug accessed through the Special Access Program (SAP).”... Read More

Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), is pleased to announce that a requested Amendment to its Controlled Substances Dealer’s Licence has been granted by Health Canada, enabling it to further expand the capacity to produce natural, GMP psilocybin at its Princeton, British... Read More

Optimi Health Corp. (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), is pleased to announce that it will be inaugurating its recently completed psilocybin cultivation facility with a grand opening event and reception for members of the media, investors and other stakeholders relevant to the Company’s developing position as a leading supplier in the field of psychedelic and functional mushrooms on Friday,... Read More

Optimi Health Corp. (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), is pleased to announce that it has commenced the cultivation of natural GMP-grade psilocybin mushrooms at its Princeton, British Columbia facility. “These mushrooms are an important milestone in Optimi’s commitment to establishing a supply of safe, natural psilocybin products for use by approved parties engaged in clinical trials,” said... Read More

Optimi Health Corp. (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN) (“ Optimi ” or the “ Company ”), developers of a vertically integrated mushroom brand targeting functional and novel psychedelic compounds for the health and wellness sector, is pleased to announce it has entered into agreements with Kydder Management Group (“ Kydder ”) and Generation IACP Inc. (“ GIACP ”) to provide services to the Company, subject to approval by the... Read More

Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated mushroom brand targeting functional and novel psychedelic compounds for the health and wellness sector, is pleased to announce the upgrade of its common shares to the OTCQX Best Market. The OTCQX Best Market represents the highest tier of OTC Markets, which operates markets on which over 11,000 U.S.... Read More

Optimi Health Corp. (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated mushroom brand targeting functional and novel psychedelic compounds for the health and wellness sector, is pleased to announce the official launch of its line of functional mushroom supplements to Canadian consumers. The B.C.-based company is transforming the health and wellness space with formulations... Read More

Optimi Health Corp. (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated mushroom brand targeting functional and novel psychedelic compounds for the health and wellness sector, is pleased to report that Health Canada has added the Company’s wholly-owned subsidiary Optimi Labs Inc. to a list of approved suppliers under the Special Access Program (SAP). With a mission to... Read More

Optimi Health Corp. (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated mushroom brand targeting functional and novel psychedelic compounds for the health and wellness sector, is pleased to report that Optimi Labs Inc., a wholly-owned subsidiary of Optimi Health Corp, been granted a Dealer’s License by Health Canada. The Dealer’s License allows for possession, production,... Read More

Optimi Health Corp. (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated mushroom brand targeting functional and novel psychedelic compounds for the health and wellness sector, is pleased to announce a second provisional patent for a proprietary two-part processing method that involves the extraction and transdermal delivery of psilocybin active components. The extraction... Read More

Optimi Health Corp. (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated mushroom brand targeting functional and novel psychedelic compounds for the health and wellness sector, is pleased to report the successful completion of the Health Canada inspection on December 21, 2021. The Company is in close contact with the regulator and welcomes finalization of the process in the... Read More

Optimi Health Corp. (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated mushroom brand targeting functional as well as novel psychedelic compounds focused on the health and wellness sector, is pleased to announce a facility inspection under the auspices of Health Canada has commenced concurrent with today’s announcement regarding the implementation and inauguration of an... Read More

Optimi Health Corp. (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated mushroom brand targeting functional as well as novel psychedelic compounds focused on the health and wellness sector, is pleased to announce it has substantially completed construction on its proposed Dealer’s License facility in Princeton, British Columbia and called for final site inspection. The... Read More

Optimi Health Corp. (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated mushroom brand targeting functional as well as novel psychedelic compounds focused on the health and wellness sector, is pleased to announce the engagement of management and communications consultants Kydder Management Group Inc. (“Kydder Group”) to assist with governmental, regulatory, corporate, and... Read More

Optimi Health Corp. (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated mushroom brand targeting functional as well as novel psychedelic compounds focused on the health and wellness sector, is pleased to announce the appointment of Valerie H. Taylor, MD, PhD as principal investigator on behalf of the University of Calgary for the proposed phase I psilocybin clinical dosing... Read More

Optimi Health Corp. (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated functional mushroom brand focused on the health and wellness sector, is pleased to advise of a recent patent filing pertaining to a breakthrough process that facilitates the extraction of the natural products Psilocybin and Psilocin from mushrooms at higher yields than previously possible. The... Read More